Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

AP-1 inhibition on the treatment of down syndrome derived aminocytes(DSACs)

ABSTRACT: AP-1 inhibition on the treatment of down syndrome derived aminocytes(DSACs)

PROVIDER: PRJNA995607 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR25305555.fastq.gz	Fastqsanger.gz
	SRR25305556.fastq.gz	Fastqsanger.gz
	SRR25305557.fastq.gz	Fastqsanger.gz
	SRR25305558.fastq.gz	Fastqsanger.gz
	SRR25305559.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 6

Similar Datasets

AP-1 inhibition on the treatment of down syndrome derived aminocytes(DSACs)

Project description:MX1 mediated AP-1 involved transcriptional regulation play an important role in the pathogenesis of DS through integration analysis of ATAC-seq and RNA-seq， therefore，AP-1 inhibition may be a potential therapeutic target for the treatment of DS-associated phenotye.

2024-01-02 | GSE237545 | GEO

Down Syndrome

Project description:Down Syndrome

| PRJNA804910 | ENA

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome

Project description:Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome

| PRJNA910594 | ENA

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome II

Project description:Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome II

| PRJNA1049466 | ENA

Down syndrome CNVs - samples

Project description:Down syndrome CNV genotyping data

| EGAD00010000466 | EGA

Down syndrome SNPs - samples

Project description:Down syndrome SNP genotyping data

| EGAD00010000464 | EGA

Epigenetic changes in Down syndrome leukemogenesis

Project description:Epigenetic changes in Down syndrome leukemogenesis

| PRJNA197487 | ENA

RNA-seq of hiPSCs derived mosaic Down syndrome (undi)

Project description:RNA-seq of hiPSCs derived mosaic Down syndrome (undi)

| PRJNA880683 | ENA

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome

Project description:Individuals with Down syndrome have a increased likelihood of suffering from inflammatory and autoimmune conditions, due to the presence of four interferon receptors on chromosome 21. Transcription of genes plays a key role in the interferon response, and the Mediator kinases, CDK8 and CDK19, are essential in potentiating this transcription. Given the role CDK8/19 play in the interferon response, and the fact that selective inhibitors of these kinases exist (such as Cortistatin A), it is possible that targetting Mediator kinase activity may alleviate symptoms of chronic inflammation in Down syndrome.

2023-09-12 | GSE220652 | GEO

Mediator kinase inhibition suppresses hyperactive interferon signaling in Down syndrome II

2024-09-01 | GSE249549 | GEO